Sanofi books over €1 billion impairment after ending eczema drug and halting two immunology programs
read at Endpoints ↗Negative
Sanofi disclosed that it will record more than €1.03 billion in impairment charges for the second quarter.
The bulk of the charge stems from the decision to terminate development of an eczema treatment that had not yet reached the market.
In a parallel pipeline review, the company also decided to cease work on two additional immunology candidates, effectively winding down those programs.
The write‑off will reduce Sanofi’s quarterly earnings and reflects a strategic shift away from the affected assets.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sanofi records €1B+ write-off, ends work on two immunology assets”
read at Endpoints ↗81 words · retrieved Jul 30
comments(0)
5-min edit window · permanent after that